Axiom Investors LLC DE Lowers Stake in Supernus Pharmaceuticals, Inc. $SUPN

Key Points

• Axiom Investors LLC DE has reduced its stake in Supernus Pharmaceuticals by 22.2% during the first quarter, owning 54,375 shares valued at approximately $1.78 million after selling 15,521 shares.
• Multiple institutional investors have increased their positions in Supernus Pharmaceuticals recently, with Barclays PLC raising its stake by 12.9% during the fourth quarter, now holding 122,849 shares.
• Supernus Pharmaceuticals has received upgrades from analysts, including a change from a "strong sell" to a "hold" rating by Zacks Research and a new price target of $46.00 set by Cantor Fitzgerald.

Axiom Investors LLC DE lowered its holdings in shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN - Free Report) by 22.2% in the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 54,375 shares of the specialty pharmaceutical company's stock after selling 15,521 shares during the period. Axiom Investors LLC DE owned 0.10% of Supernus Pharmaceuticals worth $1,781,000 as of its most recent SEC filing.

A number of other large investors have also recently bought and sold shares of the business. Vident Advisory LLC boosted its stake in Supernus Pharmaceuticals by 2.2% during the 4th quarter. Vident Advisory LLC now owns 14,392 shares of the specialty pharmaceutical company's stock worth $520,000 after purchasing an additional 309 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank boosted its stake in Supernus Pharmaceuticals by 2.4% during the 1st quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 14,664 shares of the specialty pharmaceutical company's stock worth $480,000 after purchasing an additional 350 shares during the period. Raiffeisen Bank International AG acquired a new stake in Supernus Pharmaceuticals during the 4th quarter worth $25,000. PNC Financial Services Group Inc. boosted its stake in Supernus Pharmaceuticals by 4.7% during the 1st quarter. PNC Financial Services Group Inc. now owns 16,097 shares of the specialty pharmaceutical company's stock worth $527,000 after purchasing an additional 726 shares during the period. Finally, Quantinno Capital Management LP boosted its stake in Supernus Pharmaceuticals by 11.5% during the 4th quarter. Quantinno Capital Management LP now owns 8,401 shares of the specialty pharmaceutical company's stock worth $304,000 after purchasing an additional 864 shares during the period.

Analyst Upgrades and Downgrades

SUPN has been the subject of several recent analyst reports. Zacks Research upgraded shares of Supernus Pharmaceuticals from a "strong sell" rating to a "hold" rating in a research note on Tuesday, August 19th. Piper Sandler raised their target price on shares of Supernus Pharmaceuticals from $36.00 to $40.00 and gave the stock a "neutral" rating in a research note on Friday. Wall Street Zen upgraded shares of Supernus Pharmaceuticals from a "hold" rating to a "buy" rating in a research note on Saturday, August 2nd. Finally, Cantor Fitzgerald raised their target price on shares of Supernus Pharmaceuticals from $42.00 to $46.00 and gave the stock an "overweight" rating in a research note on Wednesday, August 6th. Two equities research analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and a consensus price target of $43.00.

Insider Activity

In other Supernus Pharmaceuticals news, Director Frederick M. Hudson sold 7,457 shares of the firm's stock in a transaction dated Thursday, August 14th. The shares were sold at an average price of $42.26, for a total transaction of $315,132.82. Following the completion of the transaction, the director directly owned 46,307 shares in the company, valued at approximately $1,956,933.82. This trade represents a 13.87% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, SVP Frank Mottola sold 14,000 shares of Supernus Pharmaceuticals stock in a transaction dated Monday, August 25th. The stock was sold at an average price of $44.51, for a total transaction of $623,140.00. Following the sale, the senior vice president owned 15,496 shares of the company's stock, valued at approximately $689,726.96. This trade represents a 47.46% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 179,606 shares of company stock worth $7,617,005 in the last three months. Company insiders own 8.80% of the company's stock.

Supernus Pharmaceuticals Stock Performance

NASDAQ:SUPN traded down $0.25 during mid-day trading on Friday, hitting $45.12. 481,773 shares of the company's stock traded hands, compared to its average volume of 1,012,080. The firm's 50 day simple moving average is $36.63 and its 200 day simple moving average is $33.91. Supernus Pharmaceuticals, Inc. has a 1 year low of $29.16 and a 1 year high of $45.60. The company has a market cap of $2.53 billion, a PE ratio of 39.23 and a beta of 0.74.

About Supernus Pharmaceuticals

Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age.